The current valuation score of Marker Therapeutics Inc is 6.05, ranking 362 out of 386 in the Biotechnology & Medical Research industry. Its current P/E ratio is -2.18, which is -90.05% below the recent high of -0.22 and -292.13% above the recent low of -8.56.
P/E
Relevant data have not been disclosed by the company yet.
P/B
Relevant data have not been disclosed by the company yet.
P/S
Relevant data have not been disclosed by the company yet.
P/CF
Relevant data have not been disclosed by the company yet.